Bioactivity | Scopolamine hydrochloride is a non-selective and high affinity (≤1 nM) muscarinic antagonist that is used for the prevention of post-operative nausea and vomiting. Scopolamine readily passes the blood brain barrier. Scopolamine also reversibly inhibits 5-HT3 receptor-responses with an IC50 of 2.09 μM[1]. Scopolamine induces Alzheimer's disease-like pathology through alteration of cholinergic system[2]. |
Invitro | Scopolamine blocks nicotinic acetylcholine receptors (IC50=928 μM) and increases the expression of α7 nACh receptors. Scopolamine displays concentration-dependent competition with 0.6 nM [3H]Granisetron, yielding an average pKi of 5.17±0.24 (Ki=6.76 μM). Concentration-dependent competition of fluorescently labeled form of granisetron (G-FL) with Scopolamine gives an average pKi of 5.31±0.09 (Ki=4.90 μM).Scopolamine blocks muscarinic receptors and induces a cognitive deficit[1].Scopolamine (0.1-3 mM; for 24 hours) induces cytotoxicity, ROS generation and apoptosis of SH-SY5Y cells[2]. Cell Viability Assay[2] Cell Line: |
In Vivo | Scopolamine induces memory impairment associated with attenuation of cholinergic neurotransmission, as well as an increases of processes connected with oxidative stress in the brain[3]. Animal Model: |
Name | Scopolamine hydrochloride |
CAS | 55-16-3 |
Formula | C17H22ClNO4 |
Molar Mass | 339.81 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Martin Lochner, et al. The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors. Neuropharmacology. 2016 Sep;108:220-8. [2]. Nicha Puangmalai, et al. Neuroprotection of N-benzylcinnamide on scopolamine-induced cholinergic dysfunction in human SH-SY5Y neuroblastoma cells. Neural Regen Res. 2017 Sep;12(9):1492-1498. [3]. Barbara Budzynska, et al. Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl). 2015 Mar;232(5):931-42. |